Herbal remedies and nutritional supplements in the treatment of depression: Areview

Klinik Psikofarmakoloji Bulteni

Volumn 22, Issue 3, 2012, Pages 286-292

  Dhingra, Sameer ^a,b   Parle, Milind ^b  

^a Swift Group of Colleges   (India)

^b GURU JAMBHESHWAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

Chromium; Depression; Folate; Ginkgo biloba; Ginseng; Glutamine; Herbal remedies; Hypericum extract (St John's wort); Inositol; Nutritional supplements; Polyunsaturated fatty acids; S adenosyl L methionine; Selenium

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; CHROMIUM; DOCOSAHEXAENOIC ACID; FISH OIL; FLUOXETINE; FOLIC ACID; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLUTAMINE; HYPERICUM PERFORATUM EXTRACT; ICOSAPENTAENOIC ACID; INOSITOL; LEVO METHYLFOLATE; LINOLENIC ACID; LITHIUM; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; ORAL CONTRACEPTIVE AGENT; PLACEBO; POLYUNSATURATED FATTY ACID; PSYCHOTROPIC AGENT; S ADENOSYLMETHIONINE; SELENIUM; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANXIETY; CINAHL; COCHRANE LIBRARY; DEPRESSION; DIET SUPPLEMENTATION; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG OVERDOSE; EMBASE; FOLIC ACID DEFICIENCY; GASTROINTESTINAL SYMPTOM; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; MAJOR DEPRESSION; MEDLINE; NAUSEA; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84866842108     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.5455/bcp.20120729090446     Document Type: Review

References (39)

1. World Health Organization. WHO traditional medicines strategy 2002-2005. Geneva, Switzerland: World Health Organization; 2002.
2. Dhingra S, Parle M. Non-drug strategies in the management of depression: A comprehensive study of systematic review and metaanalysis of randomised controlled trials. J Neurosci Behav Health 2011; 3(5):66-73.
3. thed. San Francisco, CA: McGraw-Hill; 2006:1065-66.
4. Mann JJ. The medical management of depression. N Engl J Med 2005; 353:1819-34.
5. Smith AJ, Sketris I, Cooke C, Gardner D, Kisely S, Tett SE. A comparison of antidepressant use in Nova Scotia, Canada and Australia. Pharmacoepidemiol Drug Saf 2008;17(7):697-706.
6. Andrews G, Titov N. Depression is very disabling. Lancet. 2007;370(9590):808-9.
7. Thomas K, Coleman P. Use of complementary or alternative medicine in a general population in Great Britain. Results from the National Omnibus survey. J Public Health (Oxf.) 2004; 26(2):152-7.
8. Zhou SF, Lai X. An update of clinical drug interactions with the herbal antidepressant St. John's wort. Curr Drug Metab 2008;9(5):394-409.
9. Kessler RC, Soukup J, Davis RB, Foster DF, Wilkey SA, Van Rompay MI, et al. The uses of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001; 158(2):289-94.
10. Sharma U. Complementary medicine today: practitioners and patients. London, UK: Routledge; 1992.
11. Fisher P, Ward A. Complementary medicine in Europe. BMJ 1994;309(6947):107-11.
12. Jorm AF, Korten AE, Christensen H, Jacomb PA, Rodgers B, Parslow RA. Association of obesity with anxiety, depression and emotional well being: a community survey. Aust N Z J Public Health. 2003;27(4):434-40.
13. Linde K, Berner M, Kriston L. St John's wort for depression (Cochrane Review). In: The Cochrane Library, Issue 4, 2008. London:Wiley.
14. Pilkington K, Boshnakova A, Richardson J. St John's wort for depression: time for a different perspective? Complement Ther Med 2006; 14(4):268-81.
15. Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, et al. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005; 25(5):441-7.
16. Wurglics M, Lobbert SS, Dingermam T, Schubert-Zsilavecz M. Rational and traditional St. John's wort preparations: Consequences for treatment of depression. Dtsch Apoth Ztg 2003; 143(13):66-70.
17. Clement K, Covertson CR, Johnson MJ, Dearing K. St. John's wort and the treatment of mild to moderate depression: a systematic review. Holist Nurs Pract 2006; 20(4):197-203.
18. British National Formulary 61. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2011.
19. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med. 2002;136(1):42-53. Baxter K (ed), Stockley's Drug Interactions 8. [CD-ROM] London: Pharmaceutical Press, 2008.
20. Farah A. The role of L-methylfolate in depressive disorders. CNS Spectr 2009; 14(1 Suppl 2):S2-S7.
21. Morris DW, Trivedi M, Rush AJ. Folate and unipolar depression. J. Altern. Complement Med 2008; 14(3):277-85.
22. Stahl SM. Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. CNS Spectr 2007; 12(10):739-44.
23. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord 1986; 10(1):9-13.
24. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990; 336(8712):392-5.
25. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000; 60(2):121-30.
26. Passeri M, Cucinotta D, Abate G, Senin U, Ventura A, Stramba Badiale M, et al. Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a doubleblind multicenter study. Aging (Milano) 1993; 5(1):63-71.
27. Freeman MP. Omega-3 fatty acids in major depressive disorder. J Clin Psychiatry 2009; 70(Suppl 5):S7-S11.
28. Lin PY, Su KP. A meta-analytic review of double-blind, placebocontrolled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007; 68(7):1056-61.
29. Freeman MP. Omega-3 fatty acids and perinatal depression: a review of the literature and recommendations for future research. Prostaglandins Leukot. Essent. Fatty Acids 2006; 75(4-5): 291-7.
30. Kris-Etherton PM, Harris WS, Appel LJ; Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003;23(2):20-30.
31. Appleton KM, Hayward RC, Gunnell D, Peters TJ, Rogers PJ, Kessler D, Ness AR. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 2006;84(6):1308-16.
32. Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am. J. Cardiol. 2007; 99(6A):44-6.
33. Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr Psychiatry Reports 2003; 5(6):460-6.
34. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for treatment of major depressive disorder. J Clin Psychiatry 2009; 70(Suppl 5):S18-S22.
35. Thomas CS, Bottiglieri T, Edeh J, Carney MW, Reynolds EH, Toone BK. The influence of S-adenosylmethionine (SAM) on prolactin in depressed patients. Int Clin Psychopharmacol 1987;2(2):97-102.
36. Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990; 53(12):1096-8.
37. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability or oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr 2002; 76(Suppl):1172S-S6.
38. Fava M, Rosenbaum JF, Birnbaum R, Kelly K, Otto MW, MacLaughlin R. The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr Scand 1992; 86(1):42-5.
39. Taylor MJ, Wilder H, Bhagwagar Z, Geddes J. Inositol for depressive disorders (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. London: Wiley.